Lantern Pharma Inc.

DALLAS, TX · Biotech · Public

AI-driven oncology drug discovery and development platform using machine learning and genomics

Claim this profile

Follows are private to you and power your alerts

Updated · lanternpharma.com

Sector
Biotech
Headquarters
DALLAS, TX
Latest Form D
May 2026
Total capital
$2.9M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$2.9M
3 Form D · last May 2026
5 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
2
38 pending · first 2023
Rank in peer group#59 of 342

Capital timeline

2019FEDERAL ↑EQUITY ↓Cumulative $2.9M1st Form D$535K2nd Form D$2.4M
2019FEDERAL ↑EQUITY ↓Cumulative $2.9M2nd Form D$2.4M

Latest events

  • Private capital raisedForm D · SEC · 2nd filing$2.4M
  • Private capital raisedForm D · SEC · 1st filing$535K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

1 record has no date or no amount, so it isn’t placed on the timeline.

Standing among 342 peers

Line = median

Biotech · Platform

  • Granted patents#59 · top 17%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Arunkumar AsaithambiDirectorNamed in SEC Form D filings
  • David KeyserDirectorNamed in SEC Form D filings
  • David R. MargraveExecutive OfficerNamed in SEC Form D filings
  • David SilbersteinDirectorNamed in SEC Form D filings
  • Donald KeyserDirectorNamed in SEC Form D filings
  • John FucciDirectorNamed in SEC Form D filings
Show all 11 people
  • Kishor G. BhatiaExecutive OfficerNamed in SEC Form D filings
  • Lee T. SchalopDirectorNamed in SEC Form D filings
  • Maria G. MaccecchiniDirectorNamed in SEC Form D filings
  • Panna SharmaExecutive Officer, DirectorNamed in SEC Form D filings
  • Vijay G. ChandruDirectorNamed in SEC Form D filings

What it has protected

USPTO · 2 granted of 40
  • PendingLyophilized Hydroxyureamethyl AcylfulvenUSPTOApplication 19569622
  • PendingTreating Liver Cancers With Hydroxyureamethyl AcylfulveneUSPTOApplication 19546266
  • PendingTreating Cancers With Combinations Of ANTI-CD20 Antibody And AcylfulvenesUSPTOApplication 19405201
Show all 40 patent records
  • Lyophilized Hydroxyureamethyl AcylfulvenJul 23, 2026 · Application 19569622Pending
  • Treating Liver Cancers With Hydroxyureamethyl AcylfulveneJul 2, 2026 · Application 19546266Pending
  • Treating Cancers With Combinations Of ANTI-CD20 Antibody And AcylfulvenesMar 26, 2026 · Application 19405201Pending
  • Method For Treating Renal Cell Carcinoma Or CancerJan 8, 2026 · Application 19322966Pending
  • Machine Learning System And Method For Predicting Blood Brain Barrier PermeabilityJan 8, 2026 · Application 19328348Pending
  • Method For Treating Breast Cancers And Parp Resistant Breast CancersMay 22, 2025 · Application 19023098Pending
  • Treating Cancers With Combinations Of Acylfulvenes With Ibrutinib And/or BortezomibMar 27, 2025 · Application 18973932Pending
  • Computerized Systems And Methods For Ensemble Model-based Drug DiscoveryDec 26, 2024 · Application 18829920Pending
  • Treating Cancers with Combinations of Spironolactone and AcylfulvenesDec 5, 2024 · Application 18425632Pending
  • Treatment Of Brain Metastases And Cns Metastases Using Illudins Or Hydroxylureamethyl AcylfulveneOct 3, 2024 · Application 18349256Pending
  • Method For Treating Cancer With Acylfulvene And RadiationSep 12, 2024 · Application 18669238Pending
  • Treating Cancers With Combinations Of Parp Inhibitor And AcylfulvenesSep 12, 2024 · Application 18424930Pending
  • Method for Treating Blood CancersMar 14, 2024 · Application 18500032Pending
  • Method For Treating Rhabdoid TumorsDec 19, 2023 · US 11,844,772Granted
  • Illudin Analogs, Uses Thereof, And Methods For Synthesizing The SameDec 14, 2023 · Application 18238512Pending
  • Cancer Drug Sensitivity Determining MarkersSep 28, 2023 · Application 18319919Pending
  • Illudin Analogs, Uses Thereof, And Methods For Synthesizing The SameAug 29, 2023 · US 11,739,043Granted
  • Method for Determining Sensitivity to 2,2'-Dithio-bis-Ethane SulfonateJul 13, 2023 · Application 17811812Pending
  • Increasing Cancer Patient Survival Time by Administration of Dithio-Containing CompoundsJul 6, 2023 · Application 18047188Pending
  • Hydroxyureamethyl-Acylfulvene for Treating Brain Cancer or CNS CancerJun 15, 2023 · Application 17995904Pending
  • Method For Treating Pancreatic CancerJun 8, 2023 · Application 17998117Pending
  • Method For Treating Female Non-smokers With Non-small Cell Lung CancerJun 2, 2022 · Application 17469765Pending
  • Methods for the Treatment of Solid Tumor Cancers Using Illudins and BiomarkersJul 29, 2021 · Application 17230821Pending
  • Treating Cancers With Combinations Of Spironolactone And AcylfulvenesApplication PCTUS2022074297Pending
  • Treating Cancers With Combinations Of Parp Inhibitor And AcylfulvenesApplication PCTUS2022074314Pending
  • Method For Treating Breast Cancers And Parp Resistant Breast CancersApplication 63368510Pending
  • Methods for Treating Cancers With PARB Inhibitors and AcylfulvenesApplication 63365995Pending
  • Method For Treating Cancers With Ibrutinib Or Bortezomib And AcylfulvenesApplication 63366004Pending
  • Method For Treating Blood CancersApplication PCTUS2022072091Pending
  • Method For Treating Lung Cancer And Non-small Cell Lung CancerApplication PCTUS2022071676Pending
  • Ensemble Method With Machine Learning And Deep Learning For Drug DiscoveryApplication 63269148Pending
  • Treatment Of Brain Metastases And Cns Metastases Using Illudins Or Hydroxylureamethyl AcylfulveneApplication PCTUS2022070126Pending
  • Method For Treating Rhabdoid TumorsApplication PCTUS2021065441Pending
  • Method For Treating Tumors With Hydroxyureamethyl Acylfulvene And RadiationApplication 63264290Pending
  • Cancer Drug Sensitivity Determining MarkersApplication PCTUS2021072496Pending
  • Methods for Treating Cancers With PARB Inhibitors and AcylfulvenesApplication 63227260Pending
  • Methods for Treating Cancers With Spironolactone and AcylfulvenesApplication 63227257Pending
  • Method For Treating Pancreatic CancerApplication PCTUS2021031606Pending
  • Method for Treating Leukemia and Blood CancersApplication 63183519Pending
  • Method for Treating Lung Cancer and Non-Small Cell Lung CancerApplication 63173968Pending

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .